Addictions are chronic brain diseases that can be treated medically
Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.
We are headquartered in Santa Monica, with additional offices in London, UK.
In response to a growing public health need, Opiant is developing products to treat addictions and drug overdose.
Fighting the Opioid Crisis – FOX Business
October 21, 2019 – Opiant CEO Roger Crystal on The Claman Countdown discusses the fight on the opioid crisis.
Fighting the Opioid Crisis – Fox Business Network’s “Mornings with Maria”
August 3, 2018 – Opiant CEO Dr. Roger Crystal discusses NARCAN® following singer Demi Lovato’s hospitalization.
Meeting of the President’s Commission on Combating Drug Addiction and Opioid Crisis
September 27, 2017 – Opiant CEO Dr. Roger Crystal testifies before the President’s Commission on Combating Drug Addiction and the Opioid Crisis.
Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
SANTA MONICA, Calif. , Dec. 14, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from…
Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing
SANTA MONICA, Calif. , Dec. 10, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions…
Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors
SANTA MONICA, Calif. , Dec. 07, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions…
January 11, 2021 – January 15, 2021 : JP Morgan Healthcare Conference 2021
November 19, 2020 1:45 PM EST : Jefferies 2020 Virtual London Healthcare Conference
November 12, 2020 4:30 PM EST : Opiant Pharmaceuticals Third Quarter 2020 Financial Results Conference Call
Cannabinoid1 (CB‐1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose
Published in 2020 by the Journal of Neural Transmission.
Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose
Published in April 2019 by ASPET Journals.
Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects
Published in March 2019 by American College of Neuropsychopharmacology.
Lessons from a doctor and CEO on the US’s opioid crisis
April 14, 2020 – Roger Crystal set out to impact healthcare at a ‘societal’ level. The doctor who developed the NARCAN® Nasal Spray says he is proud to see its impact on the opioid crisis in the United States: the opioid overdose reversal medicine has saved a large number of lives.
Opiant donates to organizations supporting patients vulnerable to substance use disorders during COVID-19
Opiant donated $40,000 to the International Association of Fire Fighters Foundation, the Association of Recovery in Higher Education, the Harm Reduction Coalition and the UK’s Action on Addiction.